General Information of Drug (ID: DMU8ZI3)

Drug Name
PMID25656651-Compound-33b Drug Info
Cross-matching ID
PubChem CID
60143177
TTD Drug ID
DMU8ZI3

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ponatinib DMYGJQO Acute lymphoblastic leukaemia 2A85 Approved [2]
Bosutinib DMTI8YE Blast phase chronic myelogenous leukemia, BCR-ABL1 positive Approved [3]
SKI-758 DMQ8E9R Ischemia 8B10-8B11 Approved [4]
Adenosine triphosphate DM79F6G Malnutrition 5B50-5B71 Approved [5]
Saracatinib DMBLHGP Hematologic tumour 2B33.Y Phase 2 [6]
Flumatinib DM0G5O6 Chronic myelogenous leukaemia 2A20.0 Phase 2 [7]
DCC-2036 DMJKFNU Chronic myeloid leukaemia 2A20 Phase 1/2 [8]
ISIS-CRP DMQDUG4 Cardiovascular disease BA00-BE2Z Phase 1 [9]
KW-2449 DMFO7RP Acute myeloid leukaemia 2A60 Phase 1 [10]
IkT-148009 DMMJ9HY Parkinson disease 8A00.0 Phase 1 [11]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Tyrosine-protein kinase ABL1 (ABL) TT3PJMV ABL1_HUMAN Inhibitor [1]

References

1 Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412.
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3 A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
4 Synthesis and Src kinase inhibitory activity of a series of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-7-furyl-3-quinolinecarbonitriles. J Med Chem. 2006 Dec 28;49(26):7868-76.
5 Targeted chronic myeloid leukemia therapy: Seeking a cure. Am J Health Syst Pharm. 2007 Dec 15;64(24 Suppl 15):S9-15.
6 Novel dual Src/Abl inhibitors for hematologic and solid malignancies.Expert Opin Investig Drugs.2010 Aug;19(8):931-45.
7 Flumatinib, a selective inhibitor of BCR-ABL/PDGFR/KIT, effectively overcomes drug resistance of certain KIT mutants. Cancer Sci. 2014 Jan;105(1):117-25.
8 Company report (Deciphera Pharmaceuticals: Tumor-Targeted Programs and Indications)
9 Structure-based optimization of pyrazolo[3,4-d]pyrimidines as Abl inhibitors and antiproliferative agents toward human leukemia cell lines. J Med Chem. 2008 Mar 13;51(5):1252-9.
10 KW-2449, a novel multikinase inhibitor, suppresses the growth of leukemia cells with FLT3 mutations or T315I-mutated BCR/ABL translocation. Blood. 2009 Aug 20;114(8):1607-17.
11 The c-Abl inhibitor IkT-148009 suppresses neurodegeneration in mouse models of heritable and sporadic Parkinson's disease. Sci Transl Med. 2023 Jan 18;15(679):eabp9352.